Skip to main content
Novartis' Mayzent shows promise in boosting cognitive skills in MS
5/14/2019

A late-stage study of Novartis' multiple sclerosis drug Mayzent showed patients' cognitive skills improved versus with a placebo. The company has FDA approval for the drug.

Full Story: